CompletedPhase 2NCT03680092
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Studying Rare disorder potentially indicated for transplant or complication after transplantation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dimitrios Tzachanis, MD PhD
- Principal Investigator
- Dimitrios Tzachanis, MD PhDUniversity of California, San Diego
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2023
Study locations (1)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03680092 on ClinicalTrials.govOther trials for Rare disorder potentially indicated for transplant or complication after transplantation
Additional recruiting or active studies for the same condition.